Fastned Prospectus Euronext Amsterdam
Total Page:16
File Type:pdf, Size:1020Kb
FASTNED B.V. (a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, with its statutory seat in Amsterdam, the Netherlands) Admission to listing and trading on Euronext in Amsterdam Fastned B.V. (the Company or Fastned) has applied for admission to listing and trading on Euronext in Amsterdam, a regulated market operated by Euronext Amsterdam N.V. (Euronext Amsterdam) of all of the depositary receipts (the DRs) issued by Fastned Administratie Stichting (the Foundation) representing the issued and outstanding ordinary shares in the share capital of the Company with a nominal value of EUR 0.01 each (the Shares) under the symbol “FAST” (the Listing). It is expected that the Listing, subject to extension or acceleration of the timetable, will become effective and that trading in the DRs on Euronext Amsterdam will commence on 14 June 2019. At the date of this prospectus (the Prospectus), the DRs are listed on Nxchange, a regulated market of Nxchange B.V. (Nxchange). On 9 April 2019, Fastned has terminated its agreement with Nxchange. The agreement will expire at the expiration of a six month notice period. Trading remains possible on Nxchange as long as Nxchange facilitates this option on its platform. Fastned will inform the DR Holders (as defined below) who wish to migrate from Nxchange to Euronext Amsterdam (as defined below) on its website (https://ir.fastnedcharging.com/) and via the Nxchange messaging system, on how such DR Holders (as defined below) can migrate from Nxchange to Euronext Amsterdam. The Prospectus does not constitute an offer to sell, or a sollicitation of an offer to buy, any of the DRs or any other securities issued by the Company. Investing in the DRs involves risks. See “Risk Factors” for a description of the risk factors that should be carefully considered before investing in the DRs. Trades in the DRs on Euronext Amsterdam shall settle via the facilities of the Netherlands Central Institute for Giro Securities Transactions (Nederlands Centraal Instituut voor Giraal Effectenverkeer B.V. trading as Euroclear Nederland). ING Bank N.V. (ING) is acting as listing agent in connection with the Listing (the Listing Agent). The distribution of this Prospectus in certain jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves and observe any restrictions. The DRs have not been and will not be registered under the US Securities Act of 1933, as amended (the US Securities Act) or the securities laws of any state of the United States and, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. Prospective investors in the DRs should carefully read “Important Information – General”. This Prospectus constitutes a prospectus for the purposes of Article 3 of the Directive 2003/71/EC of the European Parliament and of the Council of the European Union as amended, including by Directive 2010/73/EU (the Prospectus Directive) and has been prepared in accordance with Chapter 5.1 of the Dutch Financial Supervision Act (Wet op het financieel toezicht) and the rules promulgated thereunder. The level of disclosure of this Prospectus is proportionate to this type of listing. See “Important Information – General” and “Important Information – Responsibility Statement”. This Prospectus has been approved by and filed with the AFM. Listing Agent ING This Prospectus is dated 21 May 2019 TABLE OF CONTENTS Headings Page TABLE OF CONTENTS ....................................................................................................................................... II SUMMARY ........................................................................................................................................................... 3 SAMENVATTING .............................................................................................................................................. 15 RISK FACTORS .................................................................................................................................................. 29 IMPORTANT INFORMATION .......................................................................................................................... 43 DIVIDENDS AND DIVIDEND POLICY ........................................................................................................... 50 INDUSTRY .......................................................................................................................................................... 52 BUSINESS ........................................................................................................................................................... 64 CAPITALISATION AND INDEBTEDNESS ..................................................................................................... 86 SELECTED CONSOLIDATED FINANCIAL INFORMATION ....................................................................... 88 OPERATING AND FINANCIAL REVIEW ....................................................................................................... 92 MANAGEMENT, EMPLOYEES AND CORPORATE GOVERNANCE ....................................................... 115 MAJOR SHAREHOLDERS, DR HOLDERS AND RELATED PARTY TRANSACTIONS.......................... 132 DESCRIPTION OF SHARE CAPITAL AND CORPORATE STRUCTURE .................................................. 133 THE LISTING .................................................................................................................................................... 146 TAXATION ....................................................................................................................................................... 147 GENERAL INFORMATION ............................................................................................................................. 152 DEFINED TERMS ............................................................................................................................................. 154 GLOSSARY OF TECHNICAL TERMS ........................................................................................................... 156 INDEX TO FINANCIAL STATEMENTS ........................................................................................................ 157 SUMMARY Summaries are made up of disclosure requirements known as “elements”. The elements are numbered in Sections A – E (A.1 – E.7). This summary contains all the elements required to be included in a summary for this type of security and issuer. Because some elements are not required to be addressed, there may be gaps in the numbering sequence of the elements. Even though such elements may be required to be inserted in the summary because of the type of security and issuer, it is possible that no relevant information can be given regarding such elements. In this case a short description of such elements is included in the summary with the mention of “not applicable”. Section A – Introduction and Warnings A.1 Introduction This summary should be read as an introduction to the prospectus (the Prospectus) and relating to the admission by Fastned B.V. (the Company or Fastned) to listing and warnings trading on Euronext in Amsterdam, a regulated market of Euronext Amsterdam N.V. (Euronext Amsterdam), of all the depositary receipts (the DRs) issued by Fastned Administratie Stichting (the Foundation) representing the issued and outstanding ordinary shares in the share capital of the Company with a nominal value of EUR 0.01 each (the Shares) under the symbol “FAST” (the Listing). At the date of the Prospectus, the DRs are listed on Nxchange, a regulated market of Nxchange B.V. (Nxchange). Any decision to invest in any DRs should be based on a consideration of the Prospectus as a whole by the investor and not just the summary. Where a claim relating to the information contained in, or incorporated by reference into, the Prospectus is brought before a court, the plaintiff investor might, under the national legislation of the member states of the European Economic Area, have to bear the costs of translating the Prospectus and any documents incorporated by reference therein before the legal proceedings can be initiated. Civil liability attaches only to those persons who have tabled the summary including any translation thereof, but only if the summary is misleading, inaccurate or inconsistent when read together with the other parts of the Prospectus, or it does not provide, when read together with the other parts of the Prospectus, key information in order to aid investors when considering whether to invest in the DRs. A.2 Consent of Not applicable. The Company does not consent to the use of the Prospectus for the the subsequent resale or final placements of DRs by financial intermediaries. Company Section B – Company B.1 Legal and Fastned B.V. commercial name B.2 Domicile, The Company is a private company with limited liability (besloten vennootschap met legal form, beperkte aansprakelijkheid) incorporated under the laws of the Netherlands and is legislation domiciled in the Netherlands. The Company has its statutory seat (statutaire zetel) in and country Amsterdam, the Netherlands. of incorpo- ration B.3 Current Fastned’s core activities include selling electricity to its customers at fast charging 3 operations